Literature DB >> 23979710

Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.

Marianne Berg1, Marianne Guriby2,3, Oddmund Nordgård4, Bjørn S Nedrebø1, Terje C Ahlquist2,3, Rune Smaaland4, Satu Oltedal4, Jon Arne Søreide1,5, Hartwig Kørner1,5, Ragnhild A Lothe2,3, Kjetil Søreide1,5.   

Abstract

Lymph node (LN) harvest is influenced by several factors, including tumor genetics. Microsatellite instability (MSI) is associated with improved node harvest, but the association to other genetic factors is largely unknown. Research methods included a prospective series of stage I-III colon cancer patients undergoing ex vivo sentinel-node sampling. The presence of MSI, KRAS mutations in codons 12 and 13, and BRAF V600E mutations was analyzed. Uni- and multivariate regression models for node sampling were adjusted for clinical, pathological and molecular features. Of 204 patients, 67% had an adequate harvest (≥ 12 nodes). Adequate harvest was highest in patients whose tumors exhibited MSI (79%; odds ratio [OR] 2.5, 95% confidence interval [CI] 1.2-4.9; P = 0.007) or were located in the proximal colon (73%; 2.8, 1.5-5.3; P = 0.002). In multiple linear regression, MSI was a significant predictor of the total LN count (P = 0.02). Total node count was highest for cancers with MSI and no KRAS/BRAF mutations. The independent association between MSI and a high LN count persisted for stage I and II cancers (P = 0.04). Tumor location in the proximal colon was the only significant predictor of an adequate LN harvest (adjusted OR 2.4, 95% CI 1.2-4.9; P = 0.01). An increase in the total number of nodes harvested was not associated with an increase in nodal metastasis. In conclusion, number of nodes harvested is highest for cancers of the proximal colon and with MSI. The nodal harvest associated with MSI is influenced by BRAF and KRAS genotypes, even for cancers of proximal location. Mechanisms behind the molecular diversity and node yield should be further explored.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979710      PMCID: PMC4344456          DOI: 10.2119/molmed.2013.00049

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  33 in total

1.  Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Microsatellite instability status does not predict total lymph node or negative lymph node retrieval in stage III colon cancer.

Authors:  Erin MacQuarrie; Thomas Arnason; Jennette Gruchy; Sen Yan; Arik Drucker; Weei-Yuarn Huang
Journal:  Hum Pathol       Date:  2012-02-02       Impact factor: 3.466

3.  Detection of occult metastases in sentinel lymph nodes from colon cancer patients by K-ras mutation peptide nucleic acid clamp PCR.

Authors:  Satu Oltedal; Bjørnar Gilje; Hartwig Kørner; Ole Gunnar Aasprong; Kjersti Tjensvoll; Reino Heikkilä; Rune Smaaland; Oddmund Nordgård
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

4.  Qualitative and quantitative issues of lymph nodes as prognostic factor in colon cancer.

Authors:  Torhild Veen; Bjørn S Nedrebø; Kjartan Stormark; Jon Arne Søreide; Hartwig Kørner; Kjetil Søreide
Journal:  Dig Surg       Date:  2013-04-10       Impact factor: 2.588

5.  High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations.

Authors:  Bjørnar Gilje; Reino Heikkilä; Satu Oltedal; Kjersti Tjensvoll; Oddmund Nordgård
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

Review 6.  Is lymph node count an ideal quality indicator for cancer care?

Authors:  Nancy N Baxter
Journal:  J Surg Oncol       Date:  2009-03-15       Impact factor: 3.454

7.  Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?

Authors:  Jiping Wang; Mahmoud Kulaylat; Howard Rockette; James Hassett; Ashwani Rajput; Kelli Bullard Dunn; Merril Dayton
Journal:  Ann Surg       Date:  2009-04       Impact factor: 12.969

8.  Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach.

Authors:  Oddmund Nordgård; Satu Oltedal; Hartwig Kørner; Ole Gunnar Aasprong; Kjersti Tjensvoll; Bjørnar Gilje; Reino Heikkilä
Journal:  Ann Surg       Date:  2009-04       Impact factor: 12.969

9.  Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series.

Authors:  M A Merok; T Ahlquist; E C Røyrvik; K F Tufteland; M Hektoen; O H Sjo; T Mala; A Svindland; R A Lothe; A Nesbakken
Journal:  Ann Oncol       Date:  2012-12-12       Impact factor: 32.976

10.  High lymph node yield is related to microsatellite instability in colon cancer.

Authors:  E J Th Belt; E A te Velde; O Krijgsman; R P M Brosens; M Tijssen; H F van Essen; H B A C Stockmann; H Bril; B Carvalho; B Ylstra; H J Bonjer; G A Meijer
Journal:  Ann Surg Oncol       Date:  2011-10-12       Impact factor: 5.344

View more
  19 in total

Review 1.  EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review.

Authors:  P Quirke; N P West; I D Nagtegaal
Journal:  Virchows Arch       Date:  2014-01-24       Impact factor: 4.064

2.  The association between microsatellite instability and lymph node count in colorectal cancer.

Authors:  Alexander Arnold; Matthias Kloor; Lina Jansen; Jenny Chang-Claude; Hermann Brenner; Moritz von Winterfeld; Michael Hoffmeister; Hendrik Bläker
Journal:  Virchows Arch       Date:  2017-05-23       Impact factor: 4.064

3.  The Prognostic Value of Microsatellite Instability, KRAS, BRAF and PIK3CA Mutations in Stage II Colon Cancer Patients.

Authors:  F Jeroen Vogelaar; Felice N van Erning; Marlies S Reimers; Hans van der Linden; Hans Pruijt; Adriaan J C van den Brule; Koop Bosscha
Journal:  Mol Med       Date:  2016-05-09       Impact factor: 6.354

Review 4.  Assessment of lymph node involvement in colorectal cancer.

Authors:  Mark L H Ong; John B Schofield
Journal:  World J Gastrointest Surg       Date:  2016-03-27

5.  The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff?

Authors:  Martin M Watson; Kjetil Søreide
Journal:  Mol Med       Date:  2016-05-04       Impact factor: 6.354

Review 6.  Stage migration vs immunology: The lymph node count story in colon cancer.

Authors:  Bruno Märkl
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

7.  HGUE-C-1 is an atypical and novel colon carcinoma cell line.

Authors:  Silvina Grasso; Isabel Martínez-Lacaci; Víctor Manuel Barberá; Adela Castillejo; José Luis Soto; Javier Gallego-Plazas; Natividad López-Riquelme; Pilar García-Morales; Trinidad Mata-Balaguer; José Antonio Ferragut; Miguel Saceda
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430

8.  Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.

Authors:  T T Seppälä; J P Böhm; M Friman; L Lahtinen; V M J Väyrynen; T K E Liipo; A P Ristimäki; M V J Kairaluoma; I H Kellokumpu; T H I Kuopio; J-P Mecklin
Journal:  Br J Cancer       Date:  2015-05-14       Impact factor: 7.640

9.  Primary tumour immune response and lymph node yields in colon cancer.

Authors:  Nikhil Lal; Dedrick Kok Hong Chan; Minn E Ng; Louis Vermeulen; Simon James Alexander Buczacki
Journal:  Br J Cancer       Date:  2022-01-18       Impact factor: 9.075

10.  Overall Survival of Stage III Colon Cancer with Only One Lymph Node Metastasis Is Independently Predicted by Preoperative Carcinoembryonic Antigen Level and Lymph Node Sampling Status.

Authors:  Been-Ren Lin; Yu-Lin Lin; Hong-Shiee Lai; Po-Huang Lee; King-Jen Chang; Jin-Tung Liang
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.